Prolynx
Prolynx is a biotech company in San Francisco, United States, founded in 2010. It has raised $70.0M across 1 round, most recently a $70.0M Series A in November 2025.
Homepage
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2010
- Business Model
- B2G
- Website
- prolynxinc.com
- Total Funding
- $70.0M
- Last Round
- $70.0M Series ANov 2025
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round for this company. The full record is or through the API.
About
ProLynx is a biotechnology company developing ultra-long-acting therapeutics for obesity and related metabolic diseases. Founded in 2010 by chemists from UCSF, the company's proprietary half-life extension platform enables once-monthly and once-quarterly dosing regimens, improving treatment adherence and tolerability compared to existing obesity drugs. Based in San Francisco, ProLynx raised a $70 million Series A in December 2025.
Summary
It lists 1–10 employees. It has raised $70.0M in total across 1 round, most recently a $70.0M Series A round in Nov 2025.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Nov 2025
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/prolynx"><img src="https://indexed.vc/api/badge/company/prolynx" alt="Prolynx on Indexed.vc" width="260" height="76" /></a>